GPhA Welcomes House Bill Exempting Generic Drug User Free Act Fees From Sequestration

Published Online: Monday, July 22, 2013
Follow Pharmacy_Times:

Washington, DC, July 22, 2013 -- The Generic Pharmaceutical Association (GPhA) applauds the bipartisan introduction of the FDA Safety Over Sequestration (SOS) Act (H.R. 2725) in the House of Representatives. This legislation would exempt FDA user fees, including those provided by generic manufacturers, from sequestration, the automatic federal budget cuts that went into effect in March 2013.

“One year ago, President Obama signed into law the Generic Drug User Fee Act (GDUFA),” said Ralph G. Neas, President and CEO of the Generic Pharmaceutical Association. “A landmark achievement for the generic industry, GDUFA authorizes the FDA to use private-industry-funded payments to reduce the backlog of generic drug applications, enhance safety, expedite access and promote transparency for high-quality and affordable generic drugs. All of these outcomes are at risk if user fees are subject to sequestration.

We commend the sponsors of the FDA SOS Act, Rep. Leonard Lance (R-NJ), Rep. Anna Eshoo (D-CA), Rep. Doris Matsui (D-CA), and Rep. Mike Rogers (R-MI),” continued Neas, “for recognizing that privately-funded user fees should be exempt from sequestration, and instead used to eliminate avoidable financial strain on the FDA. This vital measure would help the agency effectively carry out its mission.” GPhA joins AdvaMed, PhRMA and other industry trade groups in supporting the bill, which will improve timely access to safe and effective medicines and medical devices for all Americans.
Related Articles
The Generic Pharmaceutical Association welcomes the FDA’s proposed rule to amend its prescription drug and biological product labeling regulations to require electronic distribution of the prescribing information intended for healthcare professionals.
The Generic Pharmaceutical Association has serious concerns about the unbalanced structure of the Trans-Pacific Partnership agreement in its current form.
GPhA has agreed to support compromise automatic substitution legislation that would allow interchangeable biologics to be automatically substituted at the pharmacy. This step brings millions of Americans closer to the day when they will be able to access safe alternatives to costly biologic medicines. Indeed, Express Scripts projects savings of $250 billion in 10 years should only the 11 likeliest biosimilars enter the market.
“GPhA applauds FDA for taking helpful steps to address, and hopefully limit, scenarios in which some brand drug companies misuse Risk Evaluation and Mitigation Strategies programs to thwart competition from more affordable generic drugs. The ongoing abuse of REMS and REMS-like programs costs the American health system and its patients $5.4 billion annually, according to a study conducted by Matrix Global Advisors. Interestingly, as the United States market readies for biosimilars, this same study identifies $140 million in lost savings that would occur for every $1 billion in biologics sales.
Latest Issues